找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Chemotherapy and Radiotherapy of Gastrointestinal Tumors; Hans Otto Klein Book 1981 Springer-Verlag Berlin Heidelberg 1981 Chemotherapy.Ra

[復(fù)制鏈接]
查看: 35181|回復(fù): 46
樓主
發(fā)表于 2025-3-21 16:36:13 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors
編輯Hans Otto Klein
視頻videohttp://file.papertrans.cn/225/224968/224968.mp4
叢書(shū)名稱Recent Results in Cancer Research
圖書(shū)封面Titlebook: Chemotherapy and Radiotherapy of Gastrointestinal Tumors;  Hans Otto Klein Book 1981 Springer-Verlag Berlin Heidelberg 1981 Chemotherapy.Ra
描述Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10]. Of the few drugs which are active in the advanced disease, only 5-fluorouracil (5-FU) and razoxane ?±1,2-bis(3,4-dioxopiperazin-1-yl)propane) are suitable for long-term adjuvant treatment [2, 9]. 5-FU has been widely and intensively studied as adjuvant chemotherapy in CRC [7], but there is no unanimity that it has even the marginal influence on survival that has been claimed [3, 10]. Razoxane has not previously been tested for adjuvant or maintenance treatment in CRC. It has however a number of biological activities which might be thought useful in the treatment of residual or minimal tumours [1] and which might therefore make it useful as an adjuvant. Thus it specifically prevents tumour dissemination and metastases in some tumours and normalizes the neovasculature which the tumours induce [6, 8, 11]. The drug is not cytotoxic in the usual sense, does not affect non-dividing cells, and only blocks cell division during a brief peri
出版日期Book 1981
關(guān)鍵詞Chemotherapy; Radiotherapy; Tumor; Tumors; therapy; Radiaton Oncology
版次1
doihttps://doi.org/10.1007/978-3-642-81681-9
isbn_softcover978-3-642-81683-3
isbn_ebook978-3-642-81681-9Series ISSN 0080-0015 Series E-ISSN 2197-6767
issn_series 0080-0015
copyrightSpringer-Verlag Berlin Heidelberg 1981
The information of publication is updating

書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors影響因子(影響力)




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors影響因子(影響力)學(xué)科排名




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors被引頻次




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors被引頻次學(xué)科排名




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors年度引用




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors年度引用學(xué)科排名




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors讀者反饋




書(shū)目名稱Chemotherapy and Radiotherapy of Gastrointestinal Tumors讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:49:36 | 只看該作者
https://doi.org/10.1007/978-3-642-19146-61973. There are now 39 institutions in the Netherlands, Germany, Switzerland, Italy, Spain, France, Israel, and Belgium contributing to the various clinical trials. They have already registered 1,350 patients, of whom 950 are evaluable for the studies. Seven clinical trials are still in progress or
板凳
發(fā)表于 2025-3-22 03:11:36 | 只看該作者
地板
發(fā)表于 2025-3-22 05:54:13 | 只看該作者
https://doi.org/10.1007/978-3-642-19199-2” surgery alone often proves inadequate, many types of postoperative adjuvant procedures have been applied in an attempt to improve the long-term survival rates. Systemic adjuvant therapy generally consists of either chemotherapy or immunotherapy, and after radical surgery, the 5-year survival rates
5#
發(fā)表于 2025-3-22 12:08:32 | 只看該作者
On a Change of SU(3) into Three SU(2),U(1)azoxane. Thirty-one patients were Duke’s group A; 49 group B; 61 group C; and 17 group D; an additional four patients were randomized in error..The adjuvant group received the usual clinical care and 125 mg razoxane twice daily for 5 consecutive days (Monday–friday) every week indefinitely. Control
6#
發(fā)表于 2025-3-22 13:39:41 | 只看該作者
https://doi.org/10.1007/978-3-642-19199-2new cases of malignant RS tumors were diagnosed; of these, 1,103 were in males, representing 6% of all male malignant tumors (incidence per 100,000 = 22.6). In females, 864 new cases were diagnosed, representing 5.1% of all female tumors (incidence per 100,000 = 16.3).
7#
發(fā)表于 2025-3-22 19:43:10 | 只看該作者
On a Change of SU(3) into Three SU(2),U(1)orouracil (5-FU) [31, 32]. Furthermore, the reported long serum half-life of ftorafur of approximately 10–16 h for the beta-phase [1, 4, 10, 19, 20] makes the drug interesting for split-dose schedules. In comparison with single daily injections, split-dose administration of a drug with a long serum
8#
發(fā)表于 2025-3-23 00:01:52 | 只看該作者
9#
發(fā)表于 2025-3-23 01:38:36 | 只看該作者
10#
發(fā)表于 2025-3-23 09:03:04 | 只看該作者
Geometrical Properties of the U(1) Gaugeexpected. For this reason a comparative pharmacokinetic study of intravenous versus oral application was performed on six patients, as well as a pilot study on 13 patients with adenocarcinomas of different origins. The results show that 5-FU is absorbed rapidly. The biological availability increases
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 03:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
武威市| 丽江市| 聂荣县| 成安县| 清徐县| 三亚市| 喀什市| 沁阳市| 昌图县| 城口县| 齐河县| 杨浦区| 方山县| 来宾市| 惠安县| 东源县| 南康市| 崇左市| 钦州市| 广宁县| 信丰县| 中西区| 兰坪| 多伦县| 沙坪坝区| 军事| 怀远县| 清新县| 南乐县| 桐庐县| 密山市| 永泰县| 廊坊市| 昔阳县| 永济市| 杭锦后旗| 邳州市| 固阳县| 睢宁县| 樟树市| 岐山县|